UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

P307 La nouvelle insuline glargine U300 (Gla-300, 300 U/ml) présente à l’état d’équilibre un profil avec une durée d’action plus prolongée et stable

Diabetes & metabolism, 2014-03, Vol.40, p.A100-A100

2014

Volltextzugriff (PDF)

Single-dose new insulin glargine 300U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes

Diabetes, obesity & metabolism, 2015-03, Vol.17 (3), p.254-260

2015

Volltextzugriff (PDF)

Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes

Diabetes, obesity & metabolism, 2015-03, Vol.17 (3), p.254-260

2015

Volltextzugriff (PDF)

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer

British journal of cancer, 2006-05, Vol.94 (9), p.1293-1299

2006

Volltextzugriff (PDF)

A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)

Annals of oncology, 2006-06, Vol.17 (6), p.1007-1013

2006

Volltextzugriff (PDF)

Amino-alkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists

Current pharmaceutical design, 2002-01, Vol.8 (10), p.835-843

2002

Volltextzugriff (PDF)

Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by SLC29A4 ) and Organic Cation Transporter 1 (OCT1) (Encoded by SLC22A1 ) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: An IMI DIRECT Study

Diabetes care, 2019-06, Vol.42 (6), p.1027-1033

2019

Volltextzugriff (PDF)

Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor

Journal of clinical oncology, 2004-01, Vol.22 (1), p.175-184

2004

Volltextzugriff (PDF)

Pharmacokinetics of sarizotan after oral administration of single and repeat doses in healthy subjects

International journal of clinical pharmacology and therapeutics, 2007-05, Vol.45 (5), p.271-280

2007

Volltextzugriff (PDF)

Single‐dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in J apanese and E uropean people with type 1 diabetes

Diabetes, obesity & metabolism, 2015-03, Vol.17 (3), p.254-260

2015

Volltextzugriff (PDF)

Evaluation of the Teratogenic Potential of Valproic Acid Analogues in Transgenic Dictyostelium discoideum Strains

Toxicology in vitro, 1998-08, Vol.12 (4), p.463-469

1998

Volltextzugriff (PDF)

Effects of medicinal compounds on the differentiation of the eukaryotic microorganism Dictyostelium discoideum: Can this model be used as a screening test for reproductive toxicity in humans?

Pharmazie, 2003-03, Vol.58 (3), p.204-210

2003

Volltextzugriff (PDF)

Comparison of hysterosalpingo-foam-sonography by a new gel foam and diagnostic laparoscopy with chromopertubation in the assessment of tubal patency for the investigation of subfertility

Ultraschall in der Medizin, 2013, Vol.34 (S 01)

2013

Volltextzugriff (PDF)

Developmentally regulated promoters from Dictyostelium discoideum as molecular markers for testing potential teratogens

Pharmazie, 1996-11, Vol.51 (11), p.902-906

1996

Volltextzugriff (PDF)

A simple cytotoxicity assay using the eucaryotic microorganism Dictyostelium discoideum

Pharmazie, 1994-10, Vol.49 (10), p.759-761

1994

Volltextzugriff (PDF)

Phase I study of the humanized anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with cisplatin, 5-fluorouracil and leucovorin (PFL) in patients (pts) with advanced esophago-gastric (EG) adenocarcinoma

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.3156-3156

2005

Volltextzugriff (PDF)

A phase II Trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced Müllerian malignancies

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.3151-3151

2005

Volltextzugriff (PDF)

Phase I study of the humanized epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with ECX (epirubicin, cisplatin and capecitabine) as first line treatment for advanced oesophagogastric (OG) adenocarcinoma

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.4028-4028

2005

Volltextzugriff (PDF)

A phase I study of a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody “EMD72000 (Matuzumab)” administered weekly in Japanese patients with advanced solid tumors; safety, PK and PD results of skin biopsies

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.3077-3077

2005

Volltextzugriff (PDF)

Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD)

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.2002-2002

2004

Volltextzugriff (PDF)

Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD)

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.2002-2002

2004

Volltextzugriff (PDF)

Uptake of the anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 in tumors of subjects with head and neck squamous cell carcinoma (HNSCC)

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.3043-3043

2004

Volltextzugriff (PDF)

Uptake of the anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 in tumors of subjects with head and neck squamous cell carcinoma (HNSCC)

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.3043-3043

2004

Volltextzugriff (PDF)

Phase I study of humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 plus gemcitabine (Gem) in advanced pancreatic cancer

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.3061-3061

2004

Volltextzugriff (PDF)

A randomized phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in subjects with advanced gastrointestinal cancers

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.3018-3018

2004

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(46)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

P307 La nouvelle insuline glargine U300 (Gla-300, 300 U/ml) présente à l’état d’équilibre un profil avec une durée d’action plus prolongée et stable

Single-dose new insulin glargine 300U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes

Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer

A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)

Amino-alkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists

Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by SLC29A4 ) and Organic Cation Transporter 1 (OCT1) (Encoded by SLC22A1 ) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: An IMI DIRECT Study

Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor

Pharmacokinetics of sarizotan after oral administration of single and repeat doses in healthy subjects

Single‐dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in J apanese and E uropean people with type 1 diabetes

Evaluation of the Teratogenic Potential of Valproic Acid Analogues in Transgenic Dictyostelium discoideum Strains

Effects of medicinal compounds on the differentiation of the eukaryotic microorganism Dictyostelium discoideum: Can this model be used as a screening test for reproductive toxicity in humans?

Comparison of hysterosalpingo-foam-sonography by a new gel foam and diagnostic laparoscopy with chromopertubation in the assessment of tubal patency for the investigation of subfertility

Developmentally regulated promoters from Dictyostelium discoideum as molecular markers for testing potential teratogens

A simple cytotoxicity assay using the eucaryotic microorganism Dictyostelium discoideum

Phase I study of the humanized anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with cisplatin, 5-fluorouracil and leucovorin (PFL) in patients (pts) with advanced esophago-gastric (EG) adenocarcinoma

A phase II Trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced Müllerian malignancies

Phase I study of the humanized epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with ECX (epirubicin, cisplatin and capecitabine) as first line treatment for advanced oesophagogastric (OG) adenocarcinoma

A phase I study of a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody “EMD72000 (Matuzumab)” administered weekly in Japanese patients with advanced solid tumors; safety, PK and PD results of skin biopsies

Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD)

Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD)

Uptake of the anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 in tumors of subjects with head and neck squamous cell carcinoma (HNSCC)

Uptake of the anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 in tumors of subjects with head and neck squamous cell carcinoma (HNSCC)

Phase I study of humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 plus gemcitabine (Gem) in advanced pancreatic cancer

A randomized phase I study of the humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 in subjects with advanced gastrointestinal cancers

Suchergebnisse filtern